4.0 Article

THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM

期刊

ACTA CLINICA CROATICA
卷 61, 期 3, 页码 379-385

出版社

SESTRE MILOSRDNICE UNIV HOSPITAL
DOI: 10.20471/acc.2022.61.03.02

关键词

notulinum toxin type A; essential blepharospasm; dystonia; Blepharospasm Disability Index; Jankovic Rating Scale

向作者/读者索取更多资源

This study aimed to investigate the effect of botulinum toxin type A on patients with essential blepharospasm and their satisfaction. The results showed that the use of botulinum toxin significantly improved the quality of life and reduced the severity and frequency of symptoms.
The aim of this study was to determine the effect of botulinum toxin type A and satisfaction in patients with essential blepharospasm. The study included 12 subjects suffering from essential blepharospasm who received therapy with botulinum toxin type A injections. Respondents were given a Blepharospasm Disability Index (BSDI) survey before and three weeks after the procedure with questions related to quality of life. They were also given a Jankovic Rating Scale with questions related to the severity and frequency of symptoms. The overall level of difficulties was reduced, mean-ing the quality of life increased after the application of botulinum toxin, and the study found that the increase was statistically significant (p = 0.003). The severity of symptoms after the application of botulinum toxin was reduced, which meant that there was a decrease in the severity of the difficulties, and the study found a statistically significant difference (p=0.003). The frequency of symptoms was reduced after botulinum toxin administration, and the study revealed a statistically significant dif-ference (p = 0.012). From the results of this study, we can determine that the use of botulinum toxin type A increases the quality of life and that the severity and frequency of symptoms are statistically significantly reduced.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据